BioSpace News Archive

Wuxi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, has been appointed by International Society for Pharmaceutical Engineering (ISPE) to serve on the International Board of Directors for a two-year term.

Money raised by Clayton team members, matched by company

Argosy University, Atlanta is pleased to announce that the Bachelor of Science in Nursing (BSN) degree program at Argosy University, Atlanta was granted accreditation by the Commission on Collegiate Nursing Education (CCNE) at its most recent Board of Commissioners meeting.

Medical publications are an important and credible means of communicating relevant scientific information about a pharmaceutical company’s existing and pipeline products to healthcare professionals.

Results from multi-institutional research collaboration published in Frontiers in Genetics journal

YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US

FDA Should Also Act Quickly to Ban Menthol Cigarettes

The British Heart Foundation (BHF) is calling for world-leading researchers and innovators to enter the Big Beat Challenge, to identify and solve any of the biggest problems in heart and circulatory disease and potentially transform lives across the globe.

Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced third quarter 2018 financial results.

Mirati Therapeutics, Inc. announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C.